Navigation Links
UCSF researchers identify promising new treatment for childhood leukemia
Date:3/30/2011

An experimental drug lessens symptoms of a rare form of childhood leukemia and offers significant insight into the cellular development of the disease, according to findings from a new UCSF study. The mouse model research could spearhead the development of new leukemia therapies and paves the way for future clinical trials in humans.

"Although this drug did not produce a cure, it alleviated the symptoms of leukemia as long as the treatment was continued and delayed the development of a more aggressive disease," said senior author Benjamin Braun, MD, PhD, a pediatric cancer specialist at UCSF Benioff Children's Hospital. "Maintaining a clinical remission for as long as we can may help patients who don't have other options, and perhaps will allow us to approach this disease as a chronic, but manageable, condition."

Study results are published in the March 30, 2011, online edition of the journal Science Translational Medicine.

The study focused on a type of leukemia called juvenile myelomonocytic leukemia, or JMML. An aggressive blood cancer usually diagnosed in patients younger than 5, JMML accounts for 1 to 2 percent of all childhood leukemia cases.

The disease develops in the bone marrow and leads to an elevated white blood cell count that interferes with bone marrow's ability to produce healthy red blood cells. The abnormal increase in white blood cells occurs when genetic changes, or mutations, arise in the genes that encode proteins in a cellular signaling network called the Ras pathway. This network, controlled by the Ras protein, is a critical regulator of cell growth and a frequent target of cancerous mutations.

Currently, JMML is curable only through bone marrow transplantation, in which healthy blood stem cells are extracted from a matched donor and intravenously transplanted into the patient. Still, nearly half of patients relapse after undergoing a transplant, and others are not candidates for transplantation because of advanced illness or the lack of a suitable donor, Braun said.

The researchers treated mice genetically engineered to have JMML with a drug that inhibits a signaling protein called MEK. The drug, known as a MEK inhibitor, blocks just one of the many chemical pathways controlled by Ras. Although several pharmaceutical companies already are developing these drugs, this is the first time a MEK inhibitor has been piloted as a treatment for JMML.

Remarkably, within one week of starting treatment, leukemia symptoms in nearly all of the afflicted mice reversed. Specifically, mice that were treated with the MEK inhibitor produced more red blood cells and fewer white blood cells than untreated mice, and the anemia commonly associated with JMML also disappeared.

According to the researchers, a particularly compelling aspect of the findings is that even after treatment, the majority of the animals' blood was still being produced by the mutant cells that previously caused the disease.

"The most striking aspect of our findings was that the treatment helped the mice not by making the cancer cells go away, but by forcing them to act like normal cells, despite their mutation," said first author Natalya Lyubynska, MD, an internal medicine resident at the University of Michigan. Lyubynska completed this research in Braun's lab as a UCSF medical student, with support from the UCSF Helene and Charles Linker Fellowship and was awarded the UCSF Dean's Prize for Outstanding Student Research for this work.

Through the positive effects of treatment, the study also helps clarify the mechanism by which the Ras signaling pathway regulates cell growth and confirms that the MEK protein plays a key role in the development of JMML.

"It appears that Ras causes disease in part by producing an imbalance of the kinds of cells made in the bone marrow, and that inhibiting MEK can reverse that process," Braun said. "We hope one day to improve on these results by finding a way to completely eliminate leukemia cells. At the same time, we are also learning more about how bone marrow makes the right numbers of each type of cell every day."


'/>"/>

Contact: Kate Vidinsky
kate.vidinsky@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
2. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
3. Researchers discover new way to kill pediatric brain tumors
4. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
5. Researchers create drug to keep tumor growth switched off
6. Urine protein test might help diagnose kidney damage from lupus, UT Southwestern researchers find
7. GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen
8. Clemson researchers develop hands-free texting application
9. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
10. Researchers chart genomic map spanning over 2 dozen cancers
11. Researchers discover second protective role for tumor-suppressor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... , ... September 22, 2017 , ... On Sunday, September ... and 5K honoring Olympian, Florence Joyner, still considered the fastest woman of all time. ... Flo Jo’s daughter, Mary Joyner, will sing the National Anthem. Mary was a ...
(Date:9/22/2017)... ... ... Fenwick Agency of Plano, TX has announced the commencement of a master charity ... ‘Agents of Change’ movement. The agency pledges to select a new beneficiary every 60 ... who most need help. Their hope is to bring awareness to important local causes ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... and financial setbacks, a senior finds a new lease on life with assistance ... thousands of people resolve their problem with unsecured debt. The senior is one ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE ... Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, California, who ... and Administration at St. Thomas University in Miami, Florida, was selected from a ...
(Date:9/22/2017)... ... September 22, 2017 , ... Pullano Law Offices, a Chicago personal injury law ... been selected to serve as President of the North Suburban Bar Association for 2017-2018. ... Dinner hosted by the NSBA at the North Shore Country Club in Glenview, IL, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... -- Xyntek Inc. has announced another milestone in their continued growth and success of ... growing demands of customer engagements regionally.  ... Midwest office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest ... In ...
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
Breaking Medicine Technology: